Dr. Choueiri on Ongoing Trials of Immunotherapy in RCC

Video

Toni K. Choueiri, MD, clinical director, Lank Center for Genitourinary Oncology, director, Kidney Cancer Center, senior physician, Dana-Farber Cancer Institute, discusses some of the ongoing trials evaluating different immunotherapy agents in renal cell carcinoma.

Toni K. Choueiri, MD, clinical director, Lank Center for Genitourinary Oncology, director, Kidney Cancer Center, senior physician, Dana-Farber Cancer Institute, discusses some of the ongoing trials evaluating different immunotherapy agents in renal cell carcinoma (RCC).

Choueiri highlights one trial that is comparing a combination of nivolumab (Opdivo) plus ipilimumab (Yervoy) with sunitinib (Sutent) in patients with previously untreated metastatic RCC. Another trial is currently examining the efficacy of atezolizumab in combination with bevacizumab (Avastin) compared with sunitinib.

The takeaway message, according to Choueiri, is that the standard of care is constantly evolving. Clearly, the field is moving generally in the direction of combination treatments to treat patients with RCC.

Related Videos
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,
Guenther Koehne, MD, PhD
Alessandro Villa, DDS, PhD, MPH
Joseph Mikhael, MD
Michael Richardson, MD
Minesh Mehta, MD
Ruben Olivares, MD
Phillip J. Koo, MD